Compare · BRKR vs LAB
BRKR vs LAB
Side-by-side comparison of Bruker Corporation (BRKR) and Standard BioTools Inc. (LAB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BRKR and LAB operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- BRKR is the larger of the two at $5.60B, about 15.3x LAB ($365.2M).
- Over the past year, BRKR is down 9.2% and LAB is down 23.0% - BRKR leads by 13.8 points.
- BRKR has been more active in the news (12 items in the past 4 weeks vs 7 for LAB).
- BRKR has more recent analyst coverage (21 ratings vs 5 for LAB).
- Company
- Bruker Corporation
- Standard BioTools Inc.
- Price
- $36.77+0.12%
- $0.93+0.80%
- Market cap
- $5.60B
- $365.2M
- 1M return
- +1.96%
- +1.00%
- 1Y return
- -9.15%
- -22.97%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2011
- News (4w)
- 12
- 7
- Recent ratings
- 21
- 5
Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection. The company also provides X-ray instruments, atomic force microscopy instrumentation, fluorescence optical microscopy instruments, analytical tools for electron microscopes and X-ray metrology, defect-detection equipment for semiconductor process control, and spark optical emission spectroscopy systems, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments. In addition, it offers superconducting and non-superconducting materials and devices. The company serves academic and government research customers; pharmaceutical and biotechnology, diagnostics, chemical, food and beverage, clinical, nanotechnology, semiconductor, and other industrial companies; nonprofit laboratories; academic institutions and medical schools; contract research organizations; nonprofit and for-profit forensics, and environmental and clinical microbiology laboratories; agriculture, food, and beverage safety laboratories; hospitals and government departments; agencies; raw material manufacturers; and other businesses involved in materials analysis through direct sales forces, distributors, independent sales representatives, and other representatives. Bruker Corporation was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
Standard BioTools Inc.
Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. It offers analytical systems, such as Helios, a CyTOF system, as well as Hyperion imaging systems, Hyperion tissue imagers, and flow conductors; and assays and reagents, including Maxpar reagents, Maxpar direct immune profiling assays, Maxpar on demand reagents, and IMC panel kits for immuno-oncology. The company also provides preparatory instruments, such as Juno systems; and analytical instruments comprising Biomark HD system and EP1 system. In addition, it offers integrated fluidic circuits (IFCs), such as library preparation IFCs, Juno genotyping IFC, dynamic array IFCs, digital array IFCs, and Flex Six IFC; and assays and reagents, including Advanta RNA-Seq NGS library prep kits, Advanta Dx SARS-CoV-2 RT-PCR assays, Advanta Dx COVID-19 EASE assays, delta gene and SNP type assays, access array target-specific primers and targeted sequencing prep primers, and targeted DNA Seq library assays. Further, the company offers single cell microfluidics that comprise C1 systems; preparatory analytical instruments, which include C1 IFCs; and software solutions. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. Standard BioTools Inc. has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.
Latest BRKR
- Bruker Corporation filed SEC Form 8-K: Other Events
- Bruker Announces Date and Time of First Quarter 2026 Earnings Release and Webcast
- Bruker Spatial Biology Showcases High Fidelity Spatial Data and Integrated Multi-platform Workflows for Unprecedented Multiomic Insights at AACR 2026
- Bruker Launches MyGenius PRO® High-Throughput Sample-to-Answer Molecular Diagnostics System at ESCMID 2026
- Bruker Expands Industry-Leading MALDI Biotyper® and IR Biotyper® Workflows for Microbial Identification and Outbreak Management
- SEC Form 4 filed by Munch Mark
- Bruker Unveils New NMR Products and Workflow Solutions at ENC 2026
- SEC Form DEFA14A filed by Bruker Corporation
- SEC Form DEF 14A filed by Bruker Corporation
- SEC Form 3 filed by new insider Bernard Thierry
Latest LAB
- SEC Form DEFA14A filed by Standard BioTools Inc.
- SEC Form DEF 14A filed by Standard BioTools Inc.
- Standard BioTools Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026
- SEC Form 4 filed by Egholm Michael
- SEC Form 4 filed by Kim Hanjoon Alex
- SEC Form 4 filed by Mackay Sean
- SEC Form 10-K filed by Standard BioTools Inc.
- Director Casdin Eli was granted 52,991 shares, increasing direct ownership by 2% to 2,954,053 units (SEC Form 4)
- Director Cox Troy was granted 57,264 shares, increasing direct ownership by 18% to 376,586 units (SEC Form 4)